Cancer is a multifactorial disease governed by large numbers of correlated genetic alterations that regulate the Hallmarks of Cancer. The Next Generation Sequencing (NGS) technology allows assessment of tumor genomics at the individual gene level, dissecting the pathophysiological pathways that lead to the multiple resistances model and therefore making it a potential approach for designing the right drugs for a cancer patient, with specific dosage, at a defined time interval.
Targeted panel sequencing is capable of providing clinically informative genetic alterations at high depth and high exon coverage. The number of genes included in a targeted panel can be categorized as follow:
Genes with clinical evidence with regard to their diagnostic, therapeutic, or prognostic relevance.
Genes currently under investigation in clinical trials.
Mechanism-based genes derived from models of cell signaling activity which account for disease mechanisms or drug mechanisms of action.
© 2019 Todsyshealth. All rights reserved.